Overview

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:
All

Summary

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sunovion

Treatments:

Lurasidone Hydrochloride

Criteria

Inclusion Criteria:

- Subject has completed 6 weeks of treatment and all required assessments on the final
study visit (Visit 8) of Study D1050289 (NCT01143077).

Exclusion Criteria:

- Subject is considered by the investigator to be at imminent risk of suicide or harm to
self, others, or damage to property.

- Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see
Appendix 3 for BMI determination).